I. Adcock (London, United Kingdom), M. Kraft (New York, United States)
Pharmacological characterization of the anti-inflammatory effect of mepolizumab and benralizumab in a human ex vivo model of asthma
P. Rogliani (Roma (RM), Italy), F. Facciolo (Roma (RM), Italy), E. Melis (Roma (RM), Italy), B. Ritondo (Roma (RM), Italy), M. Gabriele (Roma (RM), Italy), A. Perduno (Roma (RM), Italy), J. Ora (Roma, Italy), L. Calzetta (Parma, Italy), J. Ora (Roma (RM), Italy)
|   |
Asthma exacerbations and eosinophilia in the UK Biobank: a Genome-Wide Association Study
A. Edris (Ghent, Belgium), K. Fawcett (Leicester, United Kingdom), I. Hall (Nottingham, United Kingdom), M. Tobin (Leicester, United Kingdom), L. Lahousse (Ghent, Belgium)
| |
Dupilumab in patients with atopic dermatitis: what effect on asthma?
M. Messekher (Toulouse, France), M. Tauber (Toulouse, France), A. Didier (Toulouse, France), L. Guilleminault (Toulouse, France)
| |
IL1RAP is an emerging target in chronic airway inflammatory diseases
G. Kasetty (Mölndal, Sweden), M. Jönsson (Mölndal, Sweden), J. Persson (Mölndal, Sweden), P. Grundevik (Mölndal, Sweden), J. Nys (Granta Park, United Kingdom), S. Cohen (Granta Park, United Kingdom), A. Borde (Granta Park, Sweden), M. Birrell (London, United Kingdom)
| |
The effect of rosuvastatin on rat models asthma, hyperlipidemia and asthma-hyperlipidemia
M. Boskabady (Mashhad, Islamic Republic of Iran), S. Saadat (Mashhad, Islamic Republic of Iran)
| |
Effect of tezepelumab on symptoms and peak expiratory flow before, during and after exacerbations in NAVIGATOR
M. Castro (Kansas City, KS, United States), N. Martin (Leicester, United Kingdom), C. Ambrose (Gaithersburg, MD, United States), S. Ponnarambil (Cambridge, United States), A. Kotalik (Gaithersburg, MD, United States), J. Llanos-Ackert (Thousand Oaks, CA, United States), S. Korn (Heidelberg, Germany)
| |
Effect of tezepelumab on exacerbation-related intravenous corticosteroid use in patients with severe, uncontrolled asthma in NAVIGATOR
A. Bourdin (Montpellier , France), N. Martin (Leicester, United Kingdom), C. Ambrose (Gaithersburg, United States), S. Ponnarambil (Cambridge, United Kingdom), G. Hunter (Cambridge, United Kingdom), N. Molfino (California, United States), B. Cook (Gaithersburg, United States)
| |
Omalizumab-treated severe allergic asthmatics have comparable small airways function to healthy controls.
H. Kalsi (London, United Kingdom), A. Hakim (London, United Kingdom), S. Meah (London, United Kingdom), P. Paredi (London, United Kingdom), M. Biddiscombee (London, United Kingdom), O. Usmani (London, United Kingdom)
| |
Efficacy of tezepelumab according to age at asthma onset in NAVIGATOR
G. Brusselle (Ghent, Belgium), J. Spahn (Wilmington, United States), G. Hunter (Cambridge, United Kingdom), N. Martin (Leicester, United Kingdom), J. Llanos-Ackert (Thousand Oaks, United States), S. Ponnarambil (Cambridge, United Kingdom)
| |
Small mobile stem cells multitargeted approach to alveoli in vivo regeneration
A. Rahmo (San Marcos, United States)
| |
Validation of sputum cytokine immunoassays in COPD
A. Mulvanny (Manchester (Greater Manchester), United Kingdom), T. Southworth (Manchester (Greater Manchester), United Kingdom), C. Pattwell (Manchester (Greater Manchester), United Kingdom), D. Singh (Manchester (Greater Manchester), United Kingdom)
| |
The role of the molecular circadian clock in Asthma
J. Teppan (Graz, Austria), I. Red (Graz, Austria), J. Schwanzer (Graz, Austria), A. Heinemann (Graz, Austria), E. Sturm (Graz, Austria)
| |
Effects of salbutamol and ipratropium on human stem-cells derived cardiomyocytes´ function
M. Scurek (Brno, Czech Republic), S. Klimovic (Brno, Czech Republic), M. Pesl (Brno, Czech Republic), J. Pribyl (Brno, Czech Republic), D. Kabanov (Brno, Czech Republic), D. Beckerova (Brno, Czech Republic), M. Bebarova (Brno, Czech Republic), V. Rotrekl (Brno, Czech Republic), K. Brat (Brno, Czech Republic)
| |
Targeting eosinophils in chronic eosinophilic pneumonia: new therapeutic perspectives for long-term control.
C. Cisternino (Roma, Italy), A. Steffanina (Roma, Italy), P. Scarano (Roma, Italy), G. Lo Muzio (Roma, Italy), O. Calò (Roma, Italy), A. Sanna (Roma, Italy), F. De Filippis (Roma, Italy), M. Leporini (Roma, Italy), P. Palange (Roma, Italy), E. Graziani (Roma, Italy)
| |
Dupilumab improves exacerbations and lung function irrespective of prior asthma exacerbations: TRAVERSE
A. Papi (Ferrara, Italy), M. Castro (Kansas City, KS, United States), W. Busse (Madison, WI, United States), D. Langton (Frankston, VIC, Australia), S. Korn (Mainz, Germany), C. Xia (Tarrytown, NY, United States), X. Soler (Tarrytown, NY, United States), N. Pandit-Abid (Bridgewater, NJ, United States), S. Siddiqui (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), P. Rowe (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States)
| |
Assessment of inhaled medications using an in vitro human alveolar microphysiological system.
E. Richardson (Cambridge, United Kingdom), H. Sze (Cambridge, United Kingdom), D. Hughes (Cambridge, United Kingdom), T. Kostrzewski (Cambridge, United Kingdom)
| |
Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma
D. Price (Singapore, Singapore), S. Burkill (Singapore, Singapore), E. Wang (Denver, United States), M. E. Wechsler (Denver, United States), E. Denton (Melbourne, Australia), T. N.Tran (Gaithersburg, United States), N. Martin (Gaithersburg, United States), R. Katial (Gaithersburg, United States), P. Barker (Gaithersburg, United States), J. Maspero (Buenos Aires , Argentina), M. Hew (Melbourne, Australia), G. Bruselle (Ghent, Belgium), G. C Christoff (Sofia, Bulgaria), M. Sadatsafavi (Vancouver, Canada), C. A. Torres-Duque (Bogotá, Colombia), C. M. Porsbjerg (Bispebjerg, Denmark), C. Ulrik (Hvidovre, Denmark), S. Hansen (Copenhagen, Denmark), A. Altraja (Tartu, Estonia), A. Bourdin (Montpellier, France), N. G. Papadopoulos (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Salvi (Pune, India), R. W Costello (Dublin , Ireland), P. Francesca (Rozzano, Italy), T. Iwanga (Osakasayama, Japan), C. Kook Rhee (Seoul, Republic of Korea), M. Al-Ahmad (Kuwait , Kuwait), D. Larenas Linnemann (Ciudad de México, Mexico), J. A Fonseca (Porto, Portugal), B. G.Cosio (Mallorca, Spain), M. Koh Siyue (Singapore , Singapore), B. Kirenga (Kampala , Uganda), C. Sheu (Taiwan, Taiwan), M. Tsai (Taiwan, Taiwan), B. Mahboub (Sharjaha, United Arab Emirates), J. Busby (Belfast, United Kingdom), L. G Heaney (Belfast, United Kingdom), P. E Pfeffer (London, United Kingdom), P. Patel (London, United Kingdom), F. Hoyte (Colorado , United States), Y. Liu (Brisbane, Australia), C. Goh (Singapore, Singapore), J. Lyu (Singapore, Singapore), T. Uthaman (Singapore, Singapore), W. Henley (Singapore, Singapore), W. Henley (United Kingdom)
| |
Dupilumab effectiveness in patients with type 2-high severe asthma and chronic rhinosinusitis with nasal polyps
S. Nolasco (Catania, Italy), R. Campisi (Catania, Italy), A. Cipolla (Catania, Italy), P. Impellizzeri (Catania, Italy), M. Bonsignore (Catania, Italy), N. Crimi (Catania, Italy), C. Crimi (Catania, Italy)
| |
Characteristics of Responders to Biologics in Patients with Severe Asthma: Based on Precision Medicine Intervention in Severe Asthma (PRISM) Study
J. Lee (Seoul, Republic of Korea), H. Kim (Seoul, Republic of Korea), J. Jung (Seoul, Republic of Korea), M. Kim (Seoul, Republic of Korea), J. Choi (Hwaseong, Republic of Korea), J. Moon (Seoul, Republic of Korea), S. Park (Seoul, Republic of Korea), S. Kim (Seongnam, Republic of Korea), M. Yang (Seoul, Republic of Korea), B. Kim (Seoul, Republic of Korea), J. Kwon (Chuncheon, Republic of Korea), H. Park (Busan, Republic of Korea), C. Park (Busan, Republic of Korea), T. Lee (Ulsan, Republic of Korea), S. Kim (Daegu, Republic of Korea), Y. Nam (Busan, Republic of Korea), H. Park (Daegu, Republic of Korea), B. Lee (Seoul, Republic of Korea), H. Kwon (Seoul, Republic of Korea), W. Song (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea), T. Kim (Seoul, Republic of Korea)
| |